Opioid-Related Disorders Clinical Trial
Official title:
Hyperalgesia in Methadone Patients: Can it be Treated?
Individuals who reduce or stop use of opioid medications are at risk for developing hyperalgesia, which is an increased sensitivity to pain. This study will compare the effectiveness of dextromethorphan, gabapentin, and oxycodone at reducing hyperalgesia in individuals addicted to opioids who are concurrently receiving methadone treatment.
Opioid medications are frequently used for the treatment of moderate to severe pain;
however, individuals who use opioids have a high risk of becoming addicted. Opioid users who
abruptly stop using opioid drugs may experience withdrawal symptoms, including drug craving,
sweating, sleep disruption, nausea, irritability, and pain. Hyperalgesia, a severe and
excessive sensitivity to pain, is a serious condition that may also occur when opioid use is
reduced or discontinued. Opioid medications affect both the pain inhibitory and facilitatory
systems, meaning that while they are effective at treating pain in many individuals, they
also have the ability to intensify pain and cause hyperalgesia in some opioid users. Three
medications, dextromethorphan, gabapentin, and oxycodone, may alleviate the symptoms of
hyperalgesia and lessen an individual's sensitivity to pain. Further research is needed to
confirm the benefits of these medications for opioid addicts. The purpose of this study is
to compare the effectiveness of dextromethorphan, gabapentin, and oxycodone at reducing
opioid-induced hyperalgesia in methadone-maintained opioid addicts.
This study will involve three separate experiments. Participants in Experiment 1 will be
randomly assigned to receive either dextromethorphan or placebo; in Experiment 2,
participants will be randomly assigned to receive either gabapentin or placebo; and in
Experiment 3, participants will be randomly assigned to receive either oxycodone or placebo.
Each experiment will last 5 weeks. All 3 experiments will begin with a screening session.
Potential participants will undergo a physical exam and an electrocardiogram. Blood and
urine will be collected for laboratory tests and drug screening. Each individual's medical
and drug history will be reviewed and psychological and opiate withdrawal symptoms will be
assessed. Individuals who complete the screening and meet all study requirements will be
permitted to continue in the study.
All participants will be maintained on methadone throughout the study. Participants will
also receive either the study medication (dextromethorphan, gabapentin, or oxycodone) or
placebo four times per day beginning on Day 5. Study visits will take place once a week. At
each visit, medications for the previous week will be accounted for and medications for the
following week will be dispensed. Questionnaires and self-reports will be completed to
assess depression levels and drug use. Urine tests will be used to screen for the presence
of drugs and alcohol. During the study, participants will take part in four pain testing
sessions to measure pain threshold and tolerance; two sessions will take place during Week 1
and another two sessions will occur during Week 5. The pain testing sessions will include a
cold pressor (CP) test and an electrical stimulation (ES) procedure. The CP test will
involve placing an arm in ice water for a short period of time; the ES procedure will
involve stimulating muscle nerve endings via electrodes placed on the skin. Immediately
after the CP and ES sessions, blood will be drawn for laboratory testing. Participants will
again complete questionnaires and self-reports, and urine samples will be collected. Gift
cards will be offered as an incentive for attending study visits and having negative drug
tests.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03950492 -
Feasibility of Deep Brain Stimulation as a Novel Treatment for Refractory Opioid Use Disorder
|
N/A | |
Completed |
NCT00000335 -
Activity Monitoring Assessment of Opiate Withdrawal - 4
|
Phase 2 | |
Active, not recruiting |
NCT03949764 -
The Kentucky Viral Hepatitis Treatment Study
|
Phase 4 | |
Enrolling by invitation |
NCT06084221 -
Fatal Overdose Review Teams - Research to Enhance Surveillance Systems
|
N/A | |
Completed |
NCT02978417 -
Feasibility Study of Extended-release Naltrexone (Vivitrol) in Drug Court Settings
|
Phase 4 | |
Withdrawn |
NCT03137030 -
A Comparison of Plasma Concentrations of Hydrocodone and Acetaminophen After Administration of Different Amounts of Tablets of a New and a Marketed Tablet Formulation in Healthy Adults
|
Phase 1 | |
Withdrawn |
NCT03137017 -
A Comparison of Plasma Concentrations of Hydrocodone and Acetaminophen After Administration of a New and a Marketed Tablet Formulation Under Fasted and Fed Conditions in Healthy Adults
|
Phase 1 | |
Completed |
NCT02282306 -
Phone Interview to Prevent Recurring Opioid Overdoses
|
N/A | |
Completed |
NCT00710385 -
Abuse Liability of Suboxone Versus Subutex
|
Phase 3 | |
Completed |
NCT00142935 -
Effectiveness of Opiate Replacement Therapy Administered Prior to Release From a Correctional Facility - 1
|
N/A | |
Completed |
NCT00218309 -
Effects of Pre-Session Supplemental Hydromorphone on Drug Seeking Behavior in Opioid Dependent Individuals
|
Phase 2 | |
Terminated |
NCT00000243 -
Effects of Buprenorphine/Naloxone in Treating Opioid Dependent Individuals Who Are Maintained on Methadone
|
N/A | |
Completed |
NCT00067184 -
Fetal Neurobehavioral Development in Methadone Maintained Pregnancies
|
||
Completed |
NCT00000264 -
Subjective/Psychomotor/ Effects of Combined Alcohol & Nitrous Oxide - 16
|
N/A | |
Completed |
NCT00000257 -
Effects of Alcohol History on Effects of Nitrous Oxide - 9
|
N/A | |
Completed |
NCT00000306 -
Dextroamphetamine as Adjunct in Cocaine/Opiate Dependent Patients - 3
|
Phase 2 | |
Completed |
NCT00000279 -
Novel Medications for Opiate Detoxification - 4
|
Phase 2 | |
Completed |
NCT00000249 -
Effects of Subanesthetic Concentrations of Nitrous Oxide - 1
|
Phase 2 | |
Recruiting |
NCT04933084 -
Pre-operative Education Modalities to Decrease Opioid Use
|
N/A | |
Recruiting |
NCT03610672 -
Mobile Intervention for Young Opioid Users
|
N/A |